Ignite Creation Date:
2025-12-25 @ 2:28 AM
Ignite Modification Date:
2026-01-25 @ 4:43 AM
Study NCT ID:
NCT00301834
Status:
COMPLETED
Last Update Posted:
2017-09-28
First Post:
2006-03-09
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
Sponsor:
University of California, San Francisco
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | de novo myelodysplastic syndromes | View |
| None | previously treated myelodysplastic syndromes | View |
| None | secondary myelodysplastic syndromes | View |
| None | childhood acute myeloid leukemia in remission | View |
| None | childhood chronic myelogenous leukemia | View |
| None | congenital amegakaryocytic thrombocytopenia | View |
| None | Diamond-Blackfan anemia | View |
| None | severe congenital neutropenia | View |
| None | secondary acute myeloid leukemia | View |
| None | chronic phase chronic myelogenous leukemia | View |
| None | childhood myelodysplastic syndromes | View |